At Roche Diabetes Care we provide a holistic, therapeutic approach called integrated Personalised Diabetes Management (iPDM). Our approach strengthens the patient care process by integrating digital solutions that quickly turn data into meaningful insights. And, we do this to facilitate stronger communication and collaboration between HCPs and people with diabetes for more timely treatment decisions.
PDM-ProValue Study Program1
Prospective, cluster-randomised, controlled interventional study program
2018
Implementing integrated Personalised Diabetes Management (iPDM), a structured and digitally supported approach to guide the therapy process through collaborative decisions between physicians and people with type 2 diabetes, is associated with significant improvements in glycaemic control.
Improvement in glycaemic control
- After 12 months, improvement in glycaemic control
(HbA1c reduction) was greater in the iPDM group - Rapid HbA1c reduction followed by stabilization
Earlier and more frequent insulin therapy adjustments
In addition, participants in the iPDM group experienced more behavioural/lifestyle recommendations than control participants:
- Diabetes training (22.3% vs. 14.1%; OR = 1.8; p = 0.045)
- Physical activity/exercise (40.4% vs. 20.3%; OR = 2.4; p = 0.0063)
- Nutrition counselling (37.0% vs. 23.3%; OR = 2.2; p = 0.013)
Summary of results
Implementing iPDM, a structured and digitally supported approach to guide the therapy process through collaborative decisions between physicians and people with type 2 diabetes, is associated with significant improvements in glycaemic control.
-
Highly significant and clinically relevant HbA1c reductions in patients following the iPDM process
-
According to physicians, the process enabled timely therapy action, which may have resulted in early improvements in glycaemic control
-
A more holistic and supportive use of data sources facilitated in the iPDM process may have resulted in better informed therapy decisions
-
Physicians perceived the iPDM process as more structured and customizable, thus facilitating even more personalisation of therapy, and potentially enhancing physician-patient interactions
PDM Connect2
Interventional, single-arm prospective multicentre study
2017
Use of the Accu‑Chek® Connect diabetes management system is associated with increased treatment satisfaction, reduced distress and improved glycaemic control among individuals with insulin-treated diabetes.
Change in diabetes treatment satisfaction (DTSQ)
- High treatment satisfaction was seen at baseline (DTSQs):
29.8±5.8 on a scale of 0-36 (0=very dissatisfied, 36=very satisfied) - Improvements in treatment satisfaction (DTSQc) were observed at 6 months, with a total mean score of 14.3±5.1, p<0.001
Change in diabetes-related distress
- Reductions in total mean Diabetes Distress Scale (DDS) scores from baseline to 6 months were observed
Change in HbA1c: all and by practice type
- Significant reductions in mean HbA1c levels from baseline to 6 months were observed
ACCRUES3
Prospective, comparative, self-controlled, randomized study
2014
Use of diabetes management software by HCPs, people with diabetes, and caregivers improves accuracy and efficiency in glucose data interpretation compared with traditional logbook data.
Improved accuracy using diabetes software
- All participants achieved greater accuracy using diabetes management software reports vs. logbook data
Reduced time reviewing diabetes information
- Participants spent less time (minutes) with each case using diabetes management software reports vs. Logbook data
Summary of results
Even without prior routine use of diabetes management software, people with diabetes, caregivers and healthcare providers:
-
Identified and utilised key diabetes information and glycaemic patterns with significantly greater accuracy and with less time using software reports compared to standard logbooks
-
Expressed a stronger preference for using diabetes software reports vs. traditional logbooks
-
Greater than 90% of participating people with diabetes and caregivers agreed that the Accu‑Chek® Connect Online reports would facilitate more helpful diabetes discussions; 97% of HCP participants agreed that the reports would optimize time during consultations
VISION4
Multicenter prospective observational study
2012
Use of pattern management with the Accu‑Chek® Smart Pix system is associated with a lower HbA1c in a primary care setting.
Improvement of medical outcome: HBA1C
- 914 study participants in patient groups: T1DM N=248; T2DM N=666
- Highly significant (p<0.0001) and clinically relevant HbA1c decrease for both T1DM and T2DM patients
- Sustained decrease in mean HbA1c for both patient groups
Improvement of process and outcome quality
Usefulness for therapy decisions*
- Time needed for therapy decision making was reduced in circa 61% of cases
- Quality of the therapy decision making process was improved in circa 79% of cases
An integral part of patient dialogue*
In people with diabetes assessed by physicians:
- Communication with patients was improved in circa 76% cases
- 64% conducted SMBG in a more structured way
- 61% improved their adherence to therapy recommendations
Values show are rounded
*Participants assessed by physicians
Summary of results
The use of the Accu-Chek Smart Pix system was found to be a valuable part of diabetes management in “real world” practice settings within the study. It facilitated:
-
Highly significant and clinically relevant HbA1c reductions sustained over time
-
Improved quality of therapy decision process with less time required by participating physicians
-
Dialogue with the person with diabetes and improved adherence by participants
-
79% of physicians desired to continue their use of the Accu-Chek Smart Pix system
STeP5
12-month, cluster multicenter study
2009
Collaborative use of structured blood glucose monitoring supports significant improvement in glycaemic control, and enables clinicians to increase frequency of treatment adjustments to support better diabetes management.
Improved glycaemic control
Structured testing and the Accu‑Chek 360º View tool support reduction of HbA1c when used collaboratively.
Intent-to-treat analysis: Change in mean HbA1c over 12 months
- Significantly greater HbA1c reduction over time in STG participants (n=256) compared with ACG participants (n=227)
- Structured monitoring intervention helped to improve HbA1c values more than the control group
Structured testing and collaborative use of the tool supported reduced postprandial excursions and better overall glycaemic control.
Intent-to-treat analysis: Comparison of 7-point glucose profiles at baseline and 12 months (STG)
- STG participant profiles showed lower average preprandial, postprandial and bedtime glucose levels (p<0.01) from month 1 to month 12
- STG participants significantly lowered mean postprandial glucose excursions at all meals
Therapy optimization6
Structured monitoring and the use of the Accu‑Chek 360º View tool enables physicians to make early and systematic therapy changes, resulting in improved glycaemic control.
- Patients who received a treatment change recommendation, such as a drug and/or lifestyle change at the Month 1 visit experienced significantly greater reductions in HbA1c
- For the entire study, out of 5 possible visits, STG patients received therapy change recommendations at 2.7 visits, while ACG patients received therapy change recommendations at 1.1 visits
Summary of results
-
This study revealed that collaborative use of the Accu‑Chek 360° View tool between non-insulin treated people with T2DM and the physician supports reduction of HbA1c and improved overall glycaemic control
-
The appropriate use of the 3-day profile structured testing tool further enables physicians to make more timely and aggressive treatment changes, resulting in better glycaemic control
-
Furthermore, participants in both groups displayed a significant improvement in well-being
Clinical studies have demonstrated improved outcomes with the use of solutions similar to RocheDiabetes Care Platform that enable iPDM.
Improved
clinical outcomes
- Reduced therapeutic inertia. 1,2,4,5
- Improved A1C with no increase in hypoglycaemia. 1,4,5
- Less glycaemic variability. 4,5
- Better postprandial control. 4,5
Efficient and
effective processes
- More frequent and timely therapy adjustments. 1,2,4-6
- Faster and more accurate decision-making. 3
- Greater clinician efficiency. 3,4
- Greater clinician satisfaction. 1,4,6
Stronger HCP and
patient collaboration
- Higher treatment satisfaction. 1,2,4
- Improved therapy adherence. 1,4
- Enhanced patient understanding. 3,4
- Improved patient empowerment for decision making. 2
Want to know more?
Connect with a Roche Diabetes Care Outcome Specialist to hear more about the RocheDiabetes Care Platform and how we can partner together to tailor a solution enabling improved patient care.
1. Kulzer B, et al. Diabetes Res Clin Pract. 2018;144:200-212; 2. Mora P, et al. Diabetes Technol Ther 2017;19(12): 715-722; 3. Hinnen DA, et al. J Diabetes Sci Technol 2015;9(2):293 301;4. Weissmann J, et al. J Diabetes Sci Technol 2016;10(1):76–84; 5. Polonsky WH,et al. Diabetes Care 2011;34(2):262–267; 6. Brotons C., et al. Poster session presented at: ATTD; 2012 February 8-11; Barcelona, Spain.